Fractyl Laboratories

OverviewSuggest Edit

Fractyl Laboratories is a company developing solutions for the treatment of chronic diseases. It is engaged in the development of a minimally invasive procedural therapy that can reverse metabolic diseases. In addition, it offers Revita DMR technology for patients with type 2 diabetes
HQLexington, MA, US

Recent NewsAll News

Latest Updates

Employees (est.) (Jan 2021)51(-1%)
Cybersecurity ratingBMore

Key People/Management at Fractyl Laboratories

Brian Dovey

Brian Dovey

Allan Will

Allan Will

Jay Caplan

Jay Caplan

Co-Founder and President
Chris Gabrieli

Chris Gabrieli

Lisa Davidson

Lisa Davidson

Chief Financial Officer
Len Rosberg

Len Rosberg

Vice President of Manufacturing
Show more

Fractyl Laboratories Office Locations

Fractyl Laboratories has an office in Lexington
Lexington, MA, US (HQ)
17 Hartwell Avenue
Show all (1)

Fractyl Laboratories Financials and Metrics

Summary Metrics

Founding Date


Fractyl Laboratories total Funding

$190.1 m

Fractyl Laboratories latest funding size

$55 m

Time since last funding

6 months ago

Fractyl Laboratories investors

Fractyl Laboratories's latest funding round in August 2020 was reported to be $55 m. In total, Fractyl Laboratories has raised $190.1 m
Show all financial metrics

Fractyl Laboratories Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Fractyl Laboratories Online and Social Media Presence

Embed Graph

Fractyl Laboratories News and Updates

Taiwania Capital leads $55m Series E round in Fractyl Laboratories

The round was joined by existing investors including Bessemer Venture Partners, General Catalyst, Domain Associates and Mithril Capital Management. The post Taiwania Capital leads $55m Series E round in Fractyl Laboratories appeared first on DealStreetAsia.

Fractyl Laboratories Blogs

Fractyl Raises $55 Million in Series E Financing to Advance Revita DMR for Type 2 Diabetes

LEXINGTON, Mass., August 6, 2020 – Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today announced a first close of $55 million in a Series E financing. The financing was led by new investor Ta…

Fractyl Announces FDA IDE Approval to Begin Pivotal Study of Revita DMR for Insulin-Treated Patients with Type 2 Diabetes

LEXINGTON, Mass., June 3, 2020 — Fractyl Laboratories Inc. (Fractyl) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) to begin a pivotal study of RevitaⓇ DMR in type 2 diabetes (T2D) patients treated …

Fractyl Announces New Clinical Data on the Mechanism of Revita DMR in Type 2 Diabetes

LEXINGTON, Mass., March 30, 2020 — Fractyl Laboratories Inc. (Fractyl) today announced clinical data that elucidate the mechanisms behind the beneficial effects and significant improvements in metabolic disease parameters for type 2 diabetes patients after one Revita® duodenal mucosal resurfacing (D…

Fractyl Announces First-Ever Commercial Availability of Revita for Type 2 Diabetes in Partnership with Leading UK Private Clinic

LEXINGTON, Mass., January 28, 2020 — Fractyl Laboratories Inc. (Fractyl) today announced its first commercial partnership with HCA Healthcare UK (United Kingdom), making its Revita® treatment commercially available for the first time for patients with type 2 diabetes. HCA Healthcare UK is the larges…

Fractyl Announces New Data from Revita-1 Clinical Study Showing Durable Benefits after a Single Treatment Through Two Years of Follow Up

LEXINGTON, Mass., November 15, 2019 — Fractyl Laboratories Inc. (Fractyl) today announced that the company will present positive results from the long-term follow-up from the Revita-1 study2 at the Diabetes Technology Meeting taking place in Bethesda, Md. The data shows that patients experienced a 1…

Fractyl Announces Revita-2 Data Showing Revita DMR Provides Statistically Significant Improvements in Blood Glucose and Liver Fat in Type 2 Diabetes with and without NAFLD

LEXINGTON, Mass., November 8, 2019 — Fractyl Laboratories Inc. (Fractyl) today announced positive results from the Revita-2 trial evaluating Revita DMR (duodenal mucosal resurfacing) for the treatment of type 2 diabetes patients with and without nonalcoholic fatty liver disease (NAFLD), of which the…
Show more

Fractyl Laboratories Frequently Asked Questions

  • When was Fractyl Laboratories founded?

    Fractyl Laboratories was founded in 2010.

  • Who are Fractyl Laboratories key executives?

    Fractyl Laboratories's key executives are Brian Dovey, Allan Will and Jay Caplan.

  • How many employees does Fractyl Laboratories have?

    Fractyl Laboratories has 51 employees.

  • Who are Fractyl Laboratories competitors?

    Competitors of Fractyl Laboratories include Auxulin Pharmaceuticals, Viatris and Applied Therapeutics.

  • Where is Fractyl Laboratories headquarters?

    Fractyl Laboratories headquarters is located at 17 Hartwell Avenue, Lexington.

  • Where are Fractyl Laboratories offices?

    Fractyl Laboratories has an office in Lexington.

  • How many offices does Fractyl Laboratories have?

    Fractyl Laboratories has 1 office.